modelTriamcinoloneAndAntisept
Extends from Pharmacolibrary.Drugs.ATC.D.D07BB03.
Information
| name: | TriamcinoloneAndAntiseptics | |
| ATC code: | D07BB03 | route: | topical |
| compartments: | 1 | |
| dosage: | 15 | mg |
| volume of distribution: | 1.5 | L |
| clearance: | 0.25 | L/h/kg |
| other parameters in model implementation | ||
Triamcinolone is a synthetic corticosteroid used for its anti-inflammatory and immunosuppressive properties. The combination with antiseptics is intended for topical use to treat skin disorders with infection risk. The D07BB03 ATC code refers to triamcinolone in combination with antiseptics, primarily employed in dermatology for eczema, dermatitis, or other inflammatory skin diseases complicated by secondary infection. This combination is approved for topical use in certain countries.
Pharmacokinetics
No published pharmacokinetic (PK) studies are available for the combination of triamcinolone and antiseptics (ATC D07BB03) in topical (dermatological) use. PK parameters are therefore estimated based on general topical properties of triamcinolone. As systemic absorption from intact skin is minimal, the following values are rough estimates for a typical adult after topical application to a limited area.
References
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)